A Crossover Study to Determine the Effect on Lung Function of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control

Exclusion Criteria

• •Patients who have been hospitalized for a COPD exacerbation in the 6 weeks prior to Visit 1 or during the run-in period
• •Patients requiring long-term oxygen therapy for chronic hypoxemia
• •Patients who have had a respiratory tract infection within 6 weeks prior to Visit
• •Patients with concomitant pulmonary disease
• •Patients with a history of asthma
• •Patients with diabetes Type I or uncontrolled diabetes Type II
• •Any patient with lung cancer or a history of lung cancer
• •Any patient with active cancer or a history of cancer with less than 5 years disease free survival time
• •Patients with a history of long QT syndrome or whose QTc interval (Bazett's) measured at Visit 1 or randomization is prolonged
• •Patients who have been vaccinated with live attenuated vaccines within 30 days prior to screening or during the run-in period.
• •Patients unable to successfully use a dry powder inhaler device, MDI or perform spirometry measurements